Results 151 to 160 of about 19,190 (266)
HemaSphere, Volume 9, Issue 7, July 2025.Abstract TP53 gene mutations (mTP53) represent a distinct molecular cohort with poor outcomes. Eprenetapopt (APR‐246) is a novel, first‐in‐class small molecule that reactivates p53 and targets cellular redox balance, ultimately inducing apoptosis and ferroptosis in mTP53 cancer cells.
David A. Sallman +32 more
wiley +1 more source
Comparative phosphoproteomic analysis of the mouse testis reveals changes in phosphopeptide abundance in response to Ppp1cc deletion [PDF]
, 2014 Male Ppp1cc knockout mice are infertile due to failure of spermatogenesis, thought to arise from a deficiency of the predominant testis isoform PPP1CC2.
MacLeod, Graham +3 more
core +2 more sources
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions
Hematological Oncology, Volume 43, Issue 4, July 2025.ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese +11 more
wiley +1 more source
CRISPR directed evolution of the spliceosome for resistance to splicing inhibitors
Genome Biology, 2019 Increasing genetic diversity via directed evolution holds great promise to accelerate trait development and crop improvement. We developed a CRISPR/Cas-based directed evolution platform in plants to evolve the rice (Oryza sativa) SF3B1 spliceosomal ...
Haroon Butt +6 more
doaj +1 more source
How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley +1 more source
Comparing Nonparametric Bayesian Tree Priors for Clonal Reconstruction of Tumors
, 2014 Statistical machine learning methods, especially nonparametric Bayesian methods, have become increasingly popular to infer clonal population structure of tumors.
Deshwar, Amit G. +2 more
core +1 more source
Mammalian Polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1 [PDF]
, 2005 Kyoichi Isono +4 more
openalex +1 more source
Effect of NPM1 Mutation Subtype and Co‐Mutation Patterns on the Outcomes of Acute Myeloid Leukemia
European Journal of Haematology, Volume 115, Issue 1, Page 29-35, July 2025.ABSTRACT Introduction NPM1 mutated AML without FLT3‐ITD is considered “favorable” per the recent ELN 2022 criteria. However, our center has been challenged with treatment‐refractory patients, prompting a search for additional prognostic factors. Methods We reviewed records of NPM1 AML patients from 2015 to 2024.
Kittika Poonsombudlert +8 more
wiley +1 more source
The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome
Asian Pacific journal of cancer prevention : APJCP, 2018 Genetic mutations in genes encoding critical component of RNA splicing machinery including SF3B1 are frequently identified and recognized as the pathogenesis in the development of myelodysplatic syndrome (MDS). In this study, PCR sequencings specific for SF3B1 exon 13, 14, 15, and 16 were performed to analyse genomic DNA isolated from bone marrow ...
Teerapong Siriboonpiputtana +9 more
openaire +3 more sources